Wick, Katherine D.
Leligdowicz, Aleksandra
Willmore, Andrew
Carrillo, Sidney A.
Ghale, Rajani
Jauregui, Alejandra
Chak, Suzanna S.
Nguyen, Viet
Lee, Deanna
Jones, Chayse
Dewar, Robin
Lane, H. Clifford
Kangelaris, Kirsten N.
Hendrickson, Carolyn M.
Liu, Kathleen D.
Sinha, Pratik
Erle, David J.
Langelier, Charles R.
Krummell, Matthew F.
Woodruff, Prescott G.
Calfee, Carolyn S.
Matthay, Michael A.
,
Abe-Jones, Yumiko
Beagle, Alexander
Bhide, Sharvari
Fragiadakis, Gabriela K.
Gonzalez, Ana
Jamdar, Omid
Jones, Norman
Lea, Tasha
Leroux, Carolyn
Milush, Jeff
Pierce, Logan
Prasad, Priya
Rashid, Sadeed
Rodriguez, Nicklaus
Sigman, Austin
Ward, Alyssa
Wilson, Michael
Funding for this research was provided by:
National Institutes of Health (U19AI077439)
Genentech (TSK-020586)
Article History
Received: 27 May 2022
Accepted: 22 August 2022
First Online: 14 September 2022
Declarations
:
: This study was approved by the UCSF Institutional Review Board, IRB 20-30497, and the COMET and IMPACC scientific leadership committees. Informed consent was obtained from study participants or a designated surrogate decision-maker when available. The Institutional Review Board granted a waiver of consent for study participants from whom direct consent could not be obtained because of death during the study or inability to contact the participant or their surrogate after three separate attempts.
: Not applicable.
: In addition to project funding below, the authors declare the following: KDW has received funding from NIH 5T32GM008440-24. AL, DJE, CRL, MFK, and PGL serve on the COMET executive committee. RD receives grant support from HHSN261201500003I. CMH receives support from NIH NHLBI 5K23HL133495 and DOD W81XWH-171-0631 outside the present work. KDL receives consultancy fees from AM Pharma, Biomerieux, BOA Medical, Neumora, and Seastar and holds stock in Amgen. PGW receives grant funding from Genentech for COVID-19 studies and consultancy fees from Sanofi, Regeneron, Astra Zeneca, Glenmark Pharmaceuticals, and Theravance. CSC receives grant support from the NIH and reports grants and personal fees from Roche/Genentech, and Bayer and personal fees from Quark Pharmaceuticals, Gen1e Life Sciences, Vasomune, Quantum Leap Healthcare Collaborative, Janssen, and Cellenkos. MAM receives grant support from NIH/NHLBI R35HL140026, NIH/NIAID OT2HL156812, Genetech-Roche, and Quantum for iSPY-ARDS and consultancy fees from Citius, Novartis, Johnson & Johnson, Gilead, and Pliant. AW, SAC, RG, AJ, SSC, VN, DL, CJ, HCL, and PS have no competing interests to disclose.